Log in or Sign up for Free to view tailored content for your specialty!
Neurorehabilitation News
FDA releases 5-year action plan to combat neurodegenerative diseases
The FDA on June 23 announced a 5-year strategy for improving and extending the lives of people with rare neurodegenerative diseases by advancing development of safe and effective medical products and facilitating access to novel treatments.
FDA committee: Evidence does not support pimavanserin for Alzheimer’s disease psychosis
Acadia Pharmaceuticals Inc. announced the outcome of the FDA advisory committee meeting on the use of pimavanserin for treating hallucinations and delusions associated with Alzheimer’s disease psychosis.
Log in or Sign up for Free to view tailored content for your specialty!
Digital tool aids stroke rehabilitation by tracking arm movements
A sensor-equipped computer program was nearly 80% effective in identifying and counting arm movements in patients undergoing stroke rehabilitation, researchers from NYU Grossman School of Medicine announced.
FDA approves polyneuropathy treatment for adults
The FDA has approved Amvuttra, an RNA interference therapeutic for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
FDA extends NDA review for ALS drug
The FDA has extended its new drug application review of AMX0035, a combination of sodium phenylbutyrate and taurursodiol for the treatment of ALS, Amylyx Pharmaceuticals Inc. announced in a press release.
Disparities in filled opioid use disorder prescriptions linked to COVID-19 pandemic
The COVID-19 pandemic was a likely cause for worsened disparities in buprenorphine and naltrexone access for opioid use disorder among minority groups compared with white patients, per a study published in JAMA Network Open.
Research suggests treatment of fibromyalgia should be tailored to individual symptoms
High efficacy and acceptability were demonstrated in both on-label and off-label medications for fibromyalgia, reinforcing the value of symptom-based treatment plans, according to a study published in JAMA Network Open.
Prenatal exposure to antiseizure therapy linked to risk for neurodevelopmental disorders
Prenatal exposure to topiramate, valproate and select duotherapies was associated with increased risk for autism spectrum disorder and intellectual disability, according to a study published in JAMA Neurology.
VeriSIM Life, Total Brain to develop drugs for broad range of neurological disorders
VeriSIM Life announced it will partner with neuroscience firm Total Brain to develop new drugs for the treatment of a wide range of neurological disorders, the company announced through a press release.
HHS announces Medicare premium increase for Aduhelm will be adjusted in 2023
HHS announced that Medicare Part B premiums paid in 2022 should be lowered in 2023 to account for an overestimate in costs related to inclusion of Aduhelm within the Medicare program for reimbursement.